布雷克斯皮普拉在儿科患者中的毒性
Mohamad Bisher Akel1, Michelle E Condren2, Sarah J Passmore3
1Pediatrics, University of Oklahoma School of Community Medicine, Tulsa, Oklahoma, USA mohamad-akel@ouhsc.edu.
BMJ case reports
|May 8, 2024
概括
儿童意外摄入布雷克斯皮普拉可能导致神经和心脏症状延迟. 长期观察对于管理儿科过量治疗至关重要,因为症状的发病时间延迟.
科学领域:
- 药理学 药理学是指药理学的学科.
- 儿科毒理学 儿科毒理学
- 临床病例报告 临床病例报告
背景情况:
- 布雷克西普拉是一种非典型的抗精神病药物,在儿童群体中研究有限.
- 超治疗性摄入布雷克斯皮普拉可能导致多系统不良反应.
- 儿童意外暴露需要了解潜在的毒性.
研究的目的:
- 在儿童意外摄入布雷克斯皮普拉后,报告延迟发作的神经和心脏毒性病例.
- 强调长期观察在治疗儿科布雷克斯皮普拉过量治疗中的重要性.
- 突出需要在怀疑儿童摄入布雷克西普拉的情况下增加临床怀疑的必要性.
主要方法:
- 一个小儿病人的病例报告,意外摄入了布雷克斯皮普拉.
- 对神经和心脏症状进行临床监测.
- 毒理学评估和管理策略.
主要成果:
- 一个孩子在摄入后24小时出现了延迟的神经和心脏症状.
- 症状表现出尽管最初缺乏急性呈现.
- 这一案例突显了布雷克斯皮普拉过量推迟毒性的可能性.
结论:
- 儿童服用布雷克西普拉过量可能会出现延迟的多系统症状.
- 怀疑的高指数和延长的观察对于管理儿科布雷克斯皮普拉摄入至关重要.
- 这一案例凸显了儿科布雷克斯皮普拉毒性管理的关键知识缺口.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
126
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
126
Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K
Antiepileptic Drugs: Potassium Channel Activators
176
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
176
Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
Psychosis: Goals of Pharmacotherapy
123
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
123


